References
- Ambrosio AF, Silva AP, Araujo A, et al. (2000). Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 406:191–201.
- Brambilla G, Mattioli F, Martelli A. (2009). Genotoxic and carcinogenic effects of antipsychotics and antidepressants. Toxicology 261:77–88.
- Castren K, Pienimaki P, Arvela P, Vahakangas K. (1996). Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. Hum Exp Toxicol 15:577–82.
- Eastmond DA, Tucker JD. (1989). Identification of aneuploidy inducing agents using cytokinesis-blocked human lymphocytes and an anti-kinetochore antibody. Environ Mol Mutagen 13:34–43.
- Elger C, Bialer M, Falcao A, et al. (2013). Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia 54:1453–61.
- Evans HJ. (1984). Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In Kilbey BJ, Legator M, Nichols W, Ramel C, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 405–27.
- Fenech M. (2000). The in vitro micronucleus technique. Mutat Res 455:81–95.
- Kontaş S, Atlı Şekeroğlu Z. (2015). Investigation of cytotoxic and genotoxic effects of the antihistaminic drug, loratadine, on human lymphocytes. Drug Chem Toxicol 38:57–62.
- Myllynen P, Pienimak P, Raunio H, Vahakangas K. (1998). Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum Exp Toxicol 17:668–76.
- Perry PE, Thompson EJ. (1984). The methodology of sister chromatid exchanges. In Kilbey BJ, Legator M, Nichols W, Ramel C, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 495–529.
- Perucca E. (2005). Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 4:781–86.
- Perucca P, Gilliam FG. (2012). Adverse effects of antiepileptic drugs. Lancet Neurol 11:792–802.
- Physicians’ Desk Reference. (2005). Physicians’ desk reference (PDR). 59th ed. Montvale (NJ): Thomson PDR.
- Sarikaya R, Yüksel M. (2008). Genotoxic assessment of oxcarbazepine and carbamazepine in drosophila wing spot test. Food Chem Toxicol 46:3159–62.
- Singh G, Driever PH, Sander JW. (2005). Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128:7–17.
- Snyder RD, Pearl GS, Mandakas G, et al. (2004). Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 43:143–58.
- Snyder RD, Ewing D, Hendry LB. (2006). DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609:47–59.
- Speit G, Haupter S. (1985). On the mechanism of differential giemsa staining of bromodeoxyuridine-substituted chromosomes. II. Differences between the demonstration of sister chromatid differentiation and replication patterns. Hum Genet 70:126–29.
- Witczak M, Kociszewska I, Wilczynski J, et al. (2010). Evaluation of chromosome aberrations, sister chromatid exchange and micronuclei in cultured cord-blood lymphocytes of newborns of women treated for epilepsy during pregnancy. Mutat Res 701:111–17.